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Abstract AcrB is an inner membrane resistance-nodula-
tion-cell division efflux pump and is part of the AcrAB–
TolC tripartite efflux system. We have determined the
crystal structure of AcrB with bound Linezolid at a reso-
lution of 3.5 A˚. The structure shows that Linezolid binds to
the A385/F386 loops of the symmetric trimer of AcrB. A
conformational change of a loop in the bottom of the
periplasmic cleft is also observed.
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PDB Protein data bank
RND Resistance nodulation division
TM Transmembrane
Introduction
AcrB, the principal multidrug transporter in E. coli, crosses
the cytoplasmic membrane and acts as a proton/drug anti-
porter. It is part of the AcrAB–TolC tripartite efflux system
consisting of an outer membrane factor, TolC, a periplas-
mic membrane fusion protein, AcrA, and the inner mem-
brane resistance-nodulation-cell division (RND) efflux
pump, AcrB. This integrated three-component molecular
complex extrudes a large variety of cytotoxic substances
such as antibiotics, organic solvents, dyes, and detergents
from the cell directly into the medium, bypassing the
periplasm and the outer membrane [1–3]. Over-expression
of the tripartite RND efflux systems is thought to be a
major factor in multidrug resistance (MDR) in Gram-neg-
ative bacteria. Effective control of this and related MDR
systems has become an emerging focus for global public
health efforts [2, 4].
AcrB is one of the most well-studied RND efflux pumps.
Crystal structures of AcrB by itself as well as several drug-
bound complexes have been structurally characterized
[5–12]. Two types of quaternary arrangement have been
observed in structures of AcrB: (1) a symmetric trimer,
formed by three identical protomers or protomer–drug
complexes; and (2) an asymmetric trimer, consisting of
three distinct protomer conformations corresponding to
three functional states of the transport cycle: access,
binding and extrusion, with drug molecules only bound to
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the binding protomer. These structures have exemplified
several drug-binding modes of AcrB and provided struc-
tural insights to the substrate transport mechanism of RND
multidrug efflux transporters.
In an effort to explore how AcrB interacts with drugs,
we have determined the crystal structure of AcrB com-
plexed with Linezolid, an oxazolidinone-type antibacterial
agent that inhibits bacterial protein synthesis by specifi-
cally binding to the 50S ribosomal subunit. Linezolid was
the first FDA-approved oxazolidinone antibiotic used for
the treatment of serious infections caused by Gram-positive
bacteria that are resistant to other antibiotics. Therefore,
this drug has been called a ‘‘reserve antibiotic’’, a drug of
last resort against potentially intractable infections [13].
Linezolid is a synthetic compound, and is therefore not
susceptible to the same mechanisms underlying bacterial
resistance against naturally occurring antibiotics. However,
it has no clinically significant effect on most Gram-nega-
tive bacteria. This is thought to be a result of relatively low
intracellular concentration of Linezolid due to efflux [14].
The intracellular concentration of Linezolid could be
increased substantially by inhibition of RND-type efflux
pumps [14]. E. coli with inactivated AcrB has been found
to be more susceptible to Linezolid than cells with an intact
pump [15]. Further, NMP (1-(1-naphthylmethyl)-pipera-
zine, a putative efflux pump inhibitor) has been shown to
reduce the MIC (minimal inhibitory concentration) of
Linezolid by fourfold for E. coli, Citrobacter freundii,
Enterobacter aerogenes and Acinetobacter baumannii [16,
17]. Although these data suggest that Linezolid can be
extruded by efflux pumps, there is no direct evidence yet to
support this hypothesis. Here, we report the crystal struc-
ture of AcrB and Linezolid complex, in which AcrB indeed
binds Linezolid in the same fashion as several other anti-
biotics that are extruded by efflux pumps.
Materials and methods
Cloning, overexpression, and purification
Wild-type AcrB with a C-terminal polyhistidine tag was
prepared as described previously [7]. Briefly, AcrB was
overproduced in E. coli JM109 with a histidine-tagged
AcrB-overexpersion plasmid pAcBH. The cells were dis-
rupted with Microfluidizer (Microfluidics Corp.) and the
membrane fractions were collected washed using several
ultracentrifugation steps at 150,000g for 90 min. Purified
membranes were solubilized in buffer containing 50 mM
Tris–HCl, pH 7.0, 10 % glycerol in 2 % n-dodecyl-b-D-
maltoside (DDM) (Anatrace). Lipids and debris were
removed by ultracentrifugation at 170,000g for 60 min.
Extracted histidine-tagged AcrB was purified with metal
affinity column chromatography equilibrated with buffer
(20 mM Tris–HCl, pH 7.5, 0.3 M NaCl, 10 % glycerol and
0.2 % DDM). The column was washed stepwise using
25 and 100 mM imidazole added to the above buffer.
Purified AcrB was eluted with 300 mM imidazole. Imid-
azole was then removed by three concentration-dilution
steps using an ultrafiltration membrane. Proteins were
concentrated to 28 mg/mL in 20 mM sodium phosphate
(pH 6.2), 10 % (v/v) glycerol and 0.2 % (w/v) DDM and
were frozen in liquid nitrogen.
Crystallization and data collection
AcrB was crystallized using the sitting-drop vapor diffusion
method with 0.1 M NaCl, Na-phosphate pH 6.2, and 8 %
PEG 4000 as crystallization reagents. Crystals of the AcrB–
Linezolid complex were obtained by soaking the AcrB
crystals in a solution containing Linezolid prior to data
collection. Linezolid stock solution (30 mM) was prepared
with water, and 6 mM Linezolid was added to a cryosolvent
containing the crystallization reagents plus 25 % glycerol.
Apo-AcrB crystals were transferred to the cryosolvent and
incubated at 21 C for 10 min before flash cooling in liquid
nitrogen. X-ray diffraction data were collected at 100 K on
the 5.0.2 beam line at the Advanced Light Source at the
Lawrence Berkeley National Laboratory with X-rays at a
wavelength of 1 A˚. The crystal diffracted better than 3.3 A˚
initially and decayed during data collection, leading to a
useful resolution of about 3.5 A˚ by the end of data collec-
tion. The diffraction data were processed with the HKL2000
program suite [18]. The AcrB–Linezolid complex belongs
to the space group R32 with cell parameters a = b =
144.7 A˚, c = 519.4 A˚. The solvent content is 74 %
assuming 1 molecule in the asymmetric unit.
Structure determination and refinement
The structure determination and refinement was con-
ducted with the Phenix program suite [19]. The apo-AcrB
crystal structure (1IWG, [7]), obtained using conditions
similar to those used here and having the same space
group and very similar cell parameters (a = b = 144.5 A˚,
c = 519.2 A˚) was used as starting model for refinement
using phenix.refine [20]. The asymmetric unit of the crystal
contains one chain of AcrB. One round of rigid-body
refinement followed by B-factor refinement yielded an
R-factor of 30.9 %. The refinement was continued with
several cycles of positional, B-factor, and TLS refinement,
and revealed clear difference density (Fig. 1a, green, con-
toured at 3r) near residue F386. Increasing the contour
level of the Fo–Fc map to 3.6 r revealed 3 separate blobs
(Fig. 1a, magenta) suggesting that the density consisted of
3 electron-dense substructures, consistent with the three
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separate electron-dense parts of Linezolid. A Linezolid was
therefore modelled into this density. In addition, residues
860–864 were rebuilt into the electron density map as they
were not modelled in the starting model. The structure was
manually inspected and minor changes were made in Coot
[21], followed by refinement until convergence. The final
refined structure has an R-factor of 25.1 % and a free-R
factor of 30.4 % for data between 50 and 3.5 A˚. These are
similar to the R-factors for the earlier AcrB structure (29.0/
35.5 %). As a comparison, the R- and free R-factors of
AcrB–Linezolid complex without TLS refinement were
29.8 and 33.7 %, respectively. Detailed statistics are shown
in Table 1. The final refined Linezolid model and density
are shown in Fig. 1b.
Structure validation and deposit
The quality of the final structure was assessed using Mol-
Probity [22] and phenix.refine. The atomic coordinates and
structure factors are available in the Protein Data Bank
under accession code 4K7Q.
Results and discussion
Overall structure of AcrB–linezolid complex
Figure 2 shows a ribbon diagram of the complex structure
of AcrB–Linezolid with Linezolid molecules shown in
space-filling models. The AcrB crystal used for Linezolid
soaking was in the R32 space group in which symmetric
trimers form in the unit cell. Each AcrB monomer contains
a transmembrane (TM) domain consisting of 12 TM heli-
ces, and two periplasmic domains, the porter domain, and
the TolC-binding domain [7]. The AcrB monomers form a
trimer which appears to be stabilized by the inter-monomer
locking loops protruding into the adjacent AcrB monomer
in the TolC binding domain. The interlocked TolC-binding
domains form a funnel-like structure at the top and a
connected tunnel at the center. The tunnel leads through the
porter domain down to the large central cavity formed by
the TM domains of the three protomers. The central cavity
is connected also to the periplasm through three vestibules
located at subunit interfaces. These vestibules have been
shown to play important roles in substrate capture and
transport [23]. A cleft at the periplasmic periphery of the
porter domain has been suggested to accommodate AcrA
[7], and has been shown to be crucial for substrate binding
and transport of AcrB [24, 25].
Each protomer of the symmetric AcrB trimer binds one
Linezolid molecule on the wall of the upper portion of the
central cavity near residues A385 and F386. The 3 rings of
the Linezolid molecule lie approximately parallel to the
F386 binding loop, allowing maximum hydrophobic con-
tact between the drug and AcrB (Fig. 3). The binding
interface buries approximately 140 A˚2 surface of Linezolid
(calculated with areaimol, [26]). Almost the whole Lin-
ezolid except for its acetamide tail participates in this
intermolecular interaction dominated by hydrophobic
stacking. Several other drugs including ethidium [12],
nafcillin [11] and ampicillin [10] also have been found to
bind to this location on the symmetric AcrB trimers.
Comparison with apo-AcrB structure
The overall structure of AcrB–Linezolid complex was very
similar to that of AcrB by itself [7]. There was a significant
local conformational difference at residues 670–675. When
superposed together, the two structures has a root-mean-
square Ca coordinate deviation of 0.4 A˚ while these resi-
dues, on the surface of the protein but not near crystal
contacts, differ by up to 4 A˚ in backbone position. These
residues reside in a loop lining the bottom of the cleft in the
porter domain thought to be important for substrate trans-
port and AcrA binding. It is possible that the change in
position of this loop between unbound and Linezolid-
Fig. 1 a Unbiased Fo–Fc
difference Fourier map
contoured at 3r (green) and
3.6r (magenta) with a Linezolid
molecule overlaid onto the
density. No Linezolid had been
modeled and refined at this
stage. b Final refined 2Fo–Fc
map contoured at 1r
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bound states may reflect a functionally important state of
AcrB, though we cannot rule out the possibility that the
shift in the 670–675 loop was due to slight differences
between crystals used for structure determination. We are
in the process of obtaining higher resolution data of the
Table 1 X-ray data and refinement statistics
Crystal parameters
Space group R 32
Cell dimensions
a, b, c (A˚) 144.7, 144.7, 519.4
a, b, c () 90, 90, 120
Matthews coefficient (A˚3/Da) 4.8
Solvent content (%) 74.2
Data collectiona
Wavelength (A˚) 1.0
Resolution (A˚) 46.6–3.5 (3.56–3.50)
Rmerge (%) 6.1 (78.8)
No. of unique reflections 25,688
No. of reflections in Rfree set 1,788
Mean redundancy 5.8 (5.9)
Overall completeness (%) 99.8 (100.0)
Mean I/r 28.0 (2.2)
Refinement residualsb
Rfree (%) 30.36 (44.0)
Rwork (%) 25.13 (35.9)
Completeness (%) 95.3 (56.1)
Model quality
RMSD bond lengths (A˚) 0.003
RMSD bond angles () 0.767
MolProbity Ramachandran
distribution
Most favored (%) 88.0
Allowed (%) 9.7
Disallowed (%) 2.3
Mean main chain B-factor (A˚2) 130
Mean overall B-factor (A˚2) 133
Mean solvent B-factor (A˚2) N/A
Model contents
Protomers in ASU 1
Protein residues A (7-498, 513-864,
869-1,036)
Ligands 1 Linezolid
No. of protein atoms 7,676
No. of ligand atoms 24
No. of water molecules 0
PDB accession code 4K7Q
Standard definitions were used for all parameters. Entries in paren-
theses report data from the limiting resolution shell. Data collection
and refinement statistics come from HKL2000 and PHENIX, respec-
tively. The abbreviations RMSD and ASU stand for root-mean-square
deviation and asymmetric unit, respectively
a All observations with I C -3rI were included in calculating data-
quality statistics. Rmerge = Rhkl Ri |Ii(hkl) - \I(hkl)[|/Rhkl Ri
Ii(hkl) where Ii(hkl) is the intensity of the ith observation and
\I(hkl)[ is the mean intensity of the reflections
b The crystallographic R factor R = Rhkl | |Fobs| - |Fcal| |/Rhkl
|Fobs|; Rfree = Rhkl | |Fobs| - |Fcal| |/Rhkl |Fobs| where all reflec-
tions belong to a test set of randomly selected data
Fig. 2 Schematic diagram of AcrB–Linezolid complex. The Linezo-
lid molecules are in colored space-filling model, viewable through
one of the vestibule tunnels. The symmetric AcrB protomers are in
ice-blue, coral, and gold ribbons. The 670–675 loops are shown in
crimson tubes as depicted. Other components of the AcrB trimer
described in the text are also labelled. This figure was created with
CCP4 mg [27]
Fig. 3 Molecular contacts of AcrB trimer and Linezolid. The view is
centered on the threefold axis on the periplasmic side looking down
the inner membrane. The helixes shown are TMs of AcrB. Residues
A385 and F386 of AcrB as well as Linezolid molecules are shown in
colored surface models. Positions of F386 and Linezolid (ZLD) are
labeled. The rest of the AcrB are in ribbons representation. The
Linezolid molecules are in green, blue, red, colors indicating
positions of C, N, O atoms, respectively. The colors are not
indications of charges or potentials. This figure was prepared with
CCP4 mg
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AcrB–Linezolid complex as well as AcrB by itself under
identical crystallization and data collection conditions.
Summary
The crystal structure of an AcrB–Linezolid complex has
been determined at a resolution of 3.5 A˚. The structure
shows that one Linezolid binds to the A385/F386 loop of
each protomer in the symmetric trimer. This loop has
previously been shown to interact with Ethidium, Nafcillin,
and Ampicillin. A conformational change is also found in a
loop at the bottom of the periplasmic cleft thought to be
important for AcrA binding and drug transport.
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